Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Capricor Therapeutics Inc. (CAPR)

5.24   -0.06 (-1.13%) 09-29 01:50
Open: 5.34 Pre. Close: 5.3
High: 5.6 Low: 5.07
Volume: 730,310 Market Cap: 103M
Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. The company is headquartered in Beverly Hills, California and currently employs 18 full-time employees. The firm focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. Its product candidate, CAP-1002, a cardiosphere-derived cell product, is being tested in the ALLSTAR Phase II clinical study on patients having suffered a myocardial infarction (MI), while the DYNAMIC clinical study is testing CAP-1002 in patients in the advanced-stage of heart failure. CAP-1002 is also being tested in the HOPE-Duchenne Phase I/II clinical study for use in connection with Duchenne muscular dystrophy-related cardiomyopathy. Cenderitide, a dual receptor natriuretic peptide agonist, is being tested in a Phase II clinical study. Exosomes are nano-sized, membrane-enclosed vesicles.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 5.607 - 5.634 5.634 - 5.661
Low: 4.995 - 5.027 5.027 - 5.058
Close: 5.18 - 5.231 5.231 - 5.282

Technical analysis

as of: 2020-09-28 4:30:43 PM
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 6.62     One year: 7.67
Support: Support1: 4.20    Support2: 3.49
Resistance: Resistance1: 5.66    Resistance2: 6.57
Pivot: 5.06
Moving Average: MA(5): 5.19     MA(20): 5.15
MA(100): 5.62     MA(250): 3.41
MACD: MACD(12,26): -0.16     Signal(9): -0.23
Stochastic oscillator: %K(14,3): 40.07     %D(3): 39.56
RSI: RSI(14): 48.36
52-week: High: 12.32  Low: 0.88  Change(%): 47.6
Average Vol(K): 3-Month: 285415  10-Days: 172630

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
CAPR has closed below upper band by 38.4%. Bollinger Bands are 51.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to CAPR's normal range. The bands have been in this narrow range for 21 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Thu, 24 Sep 2020
Capricor Therapeutics Inc. (CAPR) EPS is poised to hit -0.37 next quarter: How Investors Can Make It Count the Most? - News Daemon

Wed, 23 Sep 2020
Why Buy stock in Capricor Therapeutics, Inc. (CAPR)? - Marketing Sentinel

Wed, 23 Sep 2020
Should Capricor Therapeutics Inc (CAPR) be in Your Portfolio? - InvestorsObserver

Wed, 23 Sep 2020
Capricor Therapeutics to Present Results from the HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at the International World Muscle Society Virtual Congress 2020 - GlobeNewswire

Fri, 18 Sep 2020
Capricor Therapeutics Inc (CAPR) Stock: What Does the Chart Say? - InvestorsObserver

Fri, 18 Sep 2020
Renewed Optimism is Surrounding Capricor Therapeutics Inc. (NASDAQ:CAPR) - The Oracle Dispatch

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 20
Shares Float (M) 19
% Held by Insiders 9.21
% Held by Institutions 3.69
Shares Short (K) 1,920
Shares Short P. Month (K) 1,190

Stock Financials

EPS -1.150
EPS Est This Year -0.700
EPS Est Next Year -0.760
Book Value (p.s.) 1.610
Profit Margin
Operating Margin -1451.72
Return on Assets (ttm) -24.5
Return on Equity (ttm) -50.8
Qtrly Rev. Growth -87.8
Gross Profit (p.s.) -0.210
Sales Per Share 0.030
EBITDA (p.s.) -0.434
Qtrly Earnings Growth
Operating Cash Flow (M) -7
Levered Free Cash Flow (M) -3

Stock Valuations

PE Ratio -4.56
PEG Ratio
Price to Book value 3.25
Price to Sales 172.30
Price to Cash Flow -15.49

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.